Scarica l'app Stockscreener
50.96
5.64%
2.8276
Precedente Chiudi:
$48.13
Aprire:
$48.13
Volume 24 ore:
739.47K
Relative Volume:
0.51
Capitalizzazione di mercato:
$6.09B
Reddito:
$47.30M
Utile/perdita netta:
$-377.94M
Rapporto P/E:
-14.88
EPS:
-3.4256
Flusso di cassa netto:
$-300.64M
1 W Prestazione:
+6.91%
1M Prestazione:
+9.39%
6M Prestazione:
+17.83%
1 anno Prestazione:
+69.48%
Intervallo 1D:
$47.83
$51.30
Intervallo di 1 settimana:
$46.30
$51.30
Portata 52W:
$27.07
$51.62
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Nome
Scholar Rock Holding Corp
Settore
Industria
Telefono
857-259-3860
Indirizzo
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
50.86 | 5.77B | 47.30M | -377.94M | -300.64M | -3.4256 |
VRTX
Vertex Pharmaceuticals Inc
|
436.02 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.02 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.99 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.34 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-01-09 | Iniziato | Citigroup | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-10-09 | Iniziato | BofA Securities | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-15 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Ripresa | Jefferies | Buy |
| 2025-07-30 | Ripresa | Raymond James | Strong Buy |
| 2025-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-26 | Reiterato | H.C. Wainwright | Buy |
| 2024-10-07 | Reiterato | H.C. Wainwright | Buy |
| 2024-03-28 | Iniziato | Raymond James | Strong Buy |
| 2023-10-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Overweight |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-07-12 | Iniziato | Truist | Buy |
| 2022-03-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-03-12 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Scholar Rock Holding Corp Borsa (SRRK) Ultime notizie
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
SRRK Stock Price, Quote & Chart | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
103,191 Shares in Scholar Rock Holding Corporation $SRRK Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A. - MarketBeat
Biotech Scholar Rock to webcast Jefferies healthcare talk June 3 - Stock Titan
Three Biotechs That Are Top Takeover Targets - Yahoo Finance
iA Global Asset Management Inc. Makes New $5.43 Million Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Charles Schwab Investment Management Inc. Acquires 25,060 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Redmile Group owns 7.6% of Scholar Rock (SRRK) via funds and affiliates - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
T. Rowe Price holds 5.4% of Scholar Rock (NASDAQ: SRRK) - Stock Titan
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises - Investing.com Nigeria
Earnings call transcript: Scholar Rock Q1 2026 sees EPS miss, stock rises By Investing.com - Investing.com South Africa
Transcript : Scholar Rock Holding Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
HC Wainwright Has Positive View of Scholar Rock Q2 Earnings - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After FDA Acceptance Of Apitegromab BLA - Sahm
State of New Jersey Common Pension Fund D Buys New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
TradingKey - TradingKey
Number of shareholders of Scholar Rock Holding Corp. – FWB:2QK - TradingView
FY2029 EPS Estimates for Scholar Rock Increased by Analyst - MarketBeat
Scholar Rock (SRRK) Q1 2026 Earnings Transcript - AOL.com
Nan Fung Trinity HK Ltd. Buys 225,603 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Vanguard Group Inc. Boosts Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2026 Earnings Call Transcript - Insider Monkey
Scholar Rock Q1 Earnings Call Highlights - MarketBeat
Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results - MarketBeat
SRRK Maintained by Barclays -- Price Target Raised to $55 - GuruFocus
Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites - MSN
Scholar Rock (SRRK) Receives Positive Catalyst Watch from JPMorg - GuruFocus
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $65 - GuruFocus
UBS Group AG Sells 226,355 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Transcript : Scholar Rock Holding Corporation, Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Scholar Rock Q1 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss By Investing.com - Investing.com South Africa
Earnings call transcript: Scholar Rock’s Q1 2026 financial resilience amid earnings miss - Investing.com Nigeria
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches - TipRanks
Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.83 a Share, vs. FactSet Est of $0.80 Loss - marketscreener.com
Q1 2026 Scholar Rock Holding Corp Earnings Call Transcript - GuruFocus
Scholar Rock (NASDAQ: SRRK) details March 31 2026 quarter - Stock Titan
Scholar Rock (SRRK) boosts cash to $480M as FDA sets apitegromab PDUFA date - Stock Titan
Scholar Rock gets Sept. 30 FDA decision date for SMA drug - Stock Titan
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
MSN Money - MSN
Scholar Rock faces earnings test as apitegromab approval looms By Investing.com - Investing.com South Africa
Scholar Rock faces earnings test as apitegromab approval looms - Investing.com
Evercore ISI initiates Scholar Rock stock coverage with outperform rating By Investing.com - Investing.com Australia
Scholar Rock Holding Corp Azioni (SRRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):